Organogenesis Predicting Apligraf Approval For Diabetic Ulcers In Early 2000
This article was originally published in The Gray Sheet
Executive Summary
Organogenesis plans to file a premarket approval application supplement in late 1999 that would expand the indications for its Apligraf living skin graft to include diabetic foot ulcers, Chief Strategic Officer Alan Tuck told the New York Society of Security Analysts March 16 in New York.